<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874756</url>
  </required_header>
  <id_info>
    <org_study_id>1303010802</org_study_id>
    <nct_id>NCT01874756</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia</brief_title>
  <acronym>Beta</acronym>
  <official_title>The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this application are to determine if the selective ERβ agonist
      LY500307, when added to antipsychotic medications, improves negative and/or cognitive
      symptoms in patients with schizophrenia. The specific hypotheses to be tested are to
      determine if LY500307 is safe and well tolerated in this population and whether it elicits a
      sufficient efficacy signal to be advanced for further testing in schizophrenia. A two-stage
      Phase 1b/Phase 2a adaptive (&quot;drop the inferior dose&quot;) experimental design is ongoing that
      combines three studies (clinical dose optimization, cortical target engagement confirmation
      and efficacy and safety assessment) into a single clinical trial.

      Stage 1 was conducted in year 1 and Stage 2 will be conducted in years 2 and 3. The goal of
      Stage 1 was to identify and advance the highest dose that did not demonstrate a safety signal
      and had target selectivity as determined by lack of TT suppression. This criteria was
      fulfilled at both doses, the larger of the two (75 mg/day dose) was advanced to Stage 2.
      Furthermore, there was no suggestion of ERα receptor activation (i.e., no pattern of TT
      decreases or feminization AEs) at either dose (25 mg/day and 75 mg/day). A third arm of 150
      mg/day was added to Stage 2 for evaluation. Stage 2 results in the following three arms:
      placebo, 75 mg/day and 150 mg/day. The goals of Stage 2 are to further assess LY500307 doses
      for safety and target selectivity, confirm cortical target engagement and assess efficacy.

      Primary Aim 1: To determine if LY500307 demonstrates cortical target engagement as assessed
      by fMRI/N-back in frontal-parietal regions. Secondary measures of target engagement are fMRI
      episodic memory, Pseudo-Continuous Arterial Spin Labeling, Mismatch Negativity/evoked
      response potentials, Auditory Steady State Response, Auditory P300 and Quantitative EEG
      (QEEG).

      Primary Aim 2: To determine if LY500307 is superior to placebo for one or more of the primary
      efficacy endpoints: negative symptoms (Negative Symptom Assessment Scale - 16-item total
      score), working memory (the composite score for the Letter Number Sequencing and Spatial Span
      tests) and verbal memory (Hopkins Verbal Learning Test).

      Primary Aim 3: To determine if LY500307 reduces total testosterone (TT) plasma
      concentrations, which is indicative of loss of selectivity for ERβ and engagement of ERα,
      using the following criteria: Decrease in TT plasma concentrations of 50% from baseline in
      50% of subjects per arm treated for two consecutive post-randomization values with LY500307
      in Stage 1 and Stage 2 of the trial.

      Primary Aim 4: To assess the safety of LY500307 by determining if there are SAEs, AEs
      &quot;probably related to study drug,&quot; QTc prolongation, TT suppression (50% reduction from
      baseline) and to evaluate for other safety signals.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding ended
  </why_stopped>
  <start_date type="Actual">June 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score</measure>
    <time_frame>Baseline, week 2, week 4, week 6, week 8</time_frame>
    <description>The Negative Symptom Assessment Scale - 16-item (NSA-16) is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates subjects on 16 &quot;anchors,&quot; is a semi-structured, clinical interview, and each item is rated from 1 to 6. The total score is the sum of the 16 specific items and ranges from 16 to 96; a higher score indicates greater severity of illness. In addition, there is a global rating that represents the overall assessment of a subject's negative symptoms. The rating should not be an average of any particular behavior, but a gestalt of everything observed in the interview.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Working Memory Composite Score Changes</measure>
    <time_frame>Baseline, week 2, week 4, week 6, week 8</time_frame>
    <description>Working memory (composite score of the Wechsler Memory Scale-III: Spatial Span (WMS) and Letter Number Span (LNS) tests). WMS has 2 sections in which a subject recalls increasingly difficult sequences. The total raw score range for both sections is 0-32. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
LNS consists of 24 increasingly difficult sequences of letters and numbers that a subject is to recall and repeat back in Numeric-Alpha sequential order. The total raw score range is 0-24. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
The Working Memory composite score is calculated by summing the WMS and LNS tscores, ranging from 0-200, a higher tscore reflects better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Learning Composite Score Changes</measure>
    <time_frame>Baseline, week 2, week 4, week 6, week 8</time_frame>
    <description>Verbal learning (composite score of the Hopkins Verbal Learning Test-Revised (HVLT-R)). The HVLT-R has 3 trials in which a subject recalls has many words from a list of 12 as they can. The total number recalled for each trial is summed and the score range is between 0-36. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
The verbal learning composite score is calculated by using the HVLT-R tscore, a higher tscore reflects better performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Total Testosterone Reduction</measure>
    <time_frame>week 2, week 4, week 8</time_frame>
    <description>Number of subjects with total testosterone reduction, as defined as a decrease in total testosterone plasma concentrations of 50% from baseline for two consecutive post-randomization values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With QTc Prolongation</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Number of subjects with QTc prolongation, as defined as any subject with a change from baseline of 60 msec or greater during the active treatment phases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortical Target Engagement</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>To determine if LY500307 demonstrates cortical target engagement as assessed by changes in the N-back in frontal-parietal regions during the MRI.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>LY500307 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY500307 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 6 pills of inactive drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY500307 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY500307 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY500307 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY500307 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY500307 150mg</intervention_name>
    <description>LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
    <arm_group_label>LY500307 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY500307 75mg</intervention_name>
    <description>LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
    <arm_group_label>LY500307 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 placebo capsules daily for 8 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY500307 25mg</intervention_name>
    <description>LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
    <arm_group_label>LY500307 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years of age at study entry

          -  Male

          -  DSM IV-TR diagnosis of schizophrenia as confirmed by Structured Clinical Interview for
             DSM-IV-TR (SCID)

          -  Outpatient or inpatient status

          -  Mild to moderate overall disease severity as defined by a CGI-S score of less than or
             equal to 4 (moderately ill) at randomization

          -  Moderate levels of negative symptoms as defined by a PANSS negative symptom sub-score
             greater than or equal to 11.

          -  Clinical stability as defined by:

               1. No exacerbation of illness leading to an intensification of treatment in the
                  opinion of the investigator within four weeks prior to randomization, and

               2. No change in antipsychotic medication for at least four weeks prior to
                  randomization

        Exclusion Criteria:

          -  Subjects with current acute, serious, or unstable medical conditions, including, but
             not limited to: inadequately controlled diabetes, asthma, COPD, severe
             hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or
             immunologic disease, unstable cardiovascular disorders, malnutrition, or hepatic,
             renal gastroenterologic, respiratory, endocrinologic, neurologic, hematologic, or
             infectious diseases

          -  Known or suspected history of prostate cancer, breast cancer, or other clinically
             significant neoplastic disease (other than squamous cell or basal cell carcinoma of
             skin)

          -  Known or suspected history of deep venous thrombosis, stroke, venous thromboembolism,
             pulmonary embolism, paresis or paralysis that may be thrombogenic in origin

          -  Subjects currently receiving testosterone replacement therapy or drugs that influence
             the hypothalamus-pituitary-gonadal axis.

          -  Subjects who have clinically significant extrapyramidal signs (EPS) as defined by a
             score of &gt;20 on the Simpson-Angus Scale (SAS)

          -  Clinically significant electrocardiogram (ECG) abnormality, including, but not limited
             to, a corrected QT interval (Bazett's; QTcB) &gt;450 msec. Repeat ECGs may be conducted
             at the discretion of the principal investigator.

          -  Subjects with known medical history of Human Immunodeficiency Virus positive (HIV+)
             status

          -  Subjects with an active seizure disorder

          -  Subjects with implanted pacemaker, medication pump, vagal stimulator, deep brain
             stimulator, TENS unit, ventriculoperitoneal shunt, or other contraindication to
             undergoing an MRI scan

          -  Known IQ less than 70 based on medical history

          -  Current DSM IV-TR diagnosis of substance dependence (excluding caffeine and nicotine)

          -  Subjects who test positive for (1) Hepatitis C virus antibody or (2) Hepatitis B
             surface antigen (HBsAg) with or without positive Hepatitis B core total antibody

          -  Subjects with moderate to severe renal impairment as defined by creatinine clearance
             (CrCl) &lt; 60 ml/min (measured by the Cockcroft-Gault equation) at screening. Repeat
             evaluation may be conducted at the discretion of the Principal Investigator.

          -  Subjects with hepatic impairment as defined by liver transaminases or total bilirubin
             &gt; 3 × upper limit of normal (ULN). Repeat evaluation may be conducted at the
             discretion of the Principal Investigator.

          -  Subjects considered a high risk for suicidal acts - active suicidal ideation as
             determined by clinical interview OR any suicide attempt in 30 days prior to screening

          -  Subjects who have participated in a clinical trial with any pharmacological treatment
             intervention for which they received study-related medication in the four weeks prior
             to randomization OR subjects currently receiving treatment (within 1 dosing interval
             plus four weeks) with an investigational depot formulation of an antipsychotic
             medication

          -  Subjects who demonstrate overtly aggressive behavior or who are deemed to pose a
             substantial risk of danger in the Investigator's opinion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Breier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Center for NeuroImaging</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Biostatistics</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prevention and Recovery Center for Early Psychosis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larue D Carter Memorial Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://psychiatry.medicine.iu.edu/iupdp</url>
    <description>Indiana University Psychotic Disorders Program</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>June 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Alan Breier</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>Estrogen receptor agonist</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>negative symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT01874756/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>LY500307 25mg</title>
          <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>LY500307 75mg</title>
          <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>LY500307 150mg</title>
          <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>LY500307 25mg</title>
          <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>LY500307 75mg</title>
          <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>LY500307 150mg</title>
          <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.28" spread="12.27"/>
                    <measurement group_id="B2" value="36.64" spread="12.58"/>
                    <measurement group_id="B3" value="37.15" spread="13.67"/>
                    <measurement group_id="B4" value="37.64" spread="10.21"/>
                    <measurement group_id="B5" value="37.07" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score</title>
        <description>The Negative Symptom Assessment Scale - 16-item (NSA-16) is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates subjects on 16 &quot;anchors,&quot; is a semi-structured, clinical interview, and each item is rated from 1 to 6. The total score is the sum of the 16 specific items and ranges from 16 to 96; a higher score indicates greater severity of illness. In addition, there is a global rating that represents the overall assessment of a subject's negative symptoms. The rating should not be an average of any particular behavior, but a gestalt of everything observed in the interview.</description>
        <time_frame>Baseline, week 2, week 4, week 6, week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY500307 150mg</title>
            <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY500307 75mg</title>
            <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY500307 25mg</title>
            <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Symptom Changes - Negative Symptom Assessment Scale - 16-item (NSA-16) Total Score</title>
          <description>The Negative Symptom Assessment Scale - 16-item (NSA-16) is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates subjects on 16 &quot;anchors,&quot; is a semi-structured, clinical interview, and each item is rated from 1 to 6. The total score is the sum of the 16 specific items and ranges from 16 to 96; a higher score indicates greater severity of illness. In addition, there is a global rating that represents the overall assessment of a subject's negative symptoms. The rating should not be an average of any particular behavior, but a gestalt of everything observed in the interview.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.52" spread="11.05"/>
                    <measurement group_id="O2" value="45.34" spread="12.03"/>
                    <measurement group_id="O3" value="45.93" spread="13.99"/>
                    <measurement group_id="O4" value="46.10" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.96" spread="12.82"/>
                    <measurement group_id="O2" value="46.10" spread="14.68"/>
                    <measurement group_id="O3" value="44.82" spread="11.62"/>
                    <measurement group_id="O4" value="47.20" spread="14.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.35" spread="12.38"/>
                    <measurement group_id="O2" value="48.21" spread="14.32"/>
                    <measurement group_id="O3" value="45.30" spread="12.16"/>
                    <measurement group_id="O4" value="45.80" spread="13.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.43" spread="15.36"/>
                    <measurement group_id="O2" value="46.46" spread="15.64"/>
                    <measurement group_id="O3" value="43.19" spread="11.18"/>
                    <measurement group_id="O4" value="44.10" spread="15.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.90" spread="14.09"/>
                    <measurement group_id="O2" value="47.79" spread="16.26"/>
                    <measurement group_id="O3" value="44.12" spread="12.72"/>
                    <measurement group_id="O4" value="44.50" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Working Memory Composite Score Changes</title>
        <description>Working memory (composite score of the Wechsler Memory Scale-III: Spatial Span (WMS) and Letter Number Span (LNS) tests). WMS has 2 sections in which a subject recalls increasingly difficult sequences. The total raw score range for both sections is 0-32. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
LNS consists of 24 increasingly difficult sequences of letters and numbers that a subject is to recall and repeat back in Numeric-Alpha sequential order. The total raw score range is 0-24. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
The Working Memory composite score is calculated by summing the WMS and LNS tscores, ranging from 0-200, a higher tscore reflects better performance.</description>
        <time_frame>Baseline, week 2, week 4, week 6, week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY500307 150mg</title>
            <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY500307 75mg</title>
            <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY500307 25mg</title>
            <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Working Memory Composite Score Changes</title>
          <description>Working memory (composite score of the Wechsler Memory Scale-III: Spatial Span (WMS) and Letter Number Span (LNS) tests). WMS has 2 sections in which a subject recalls increasingly difficult sequences. The total raw score range for both sections is 0-32. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
LNS consists of 24 increasingly difficult sequences of letters and numbers that a subject is to recall and repeat back in Numeric-Alpha sequential order. The total raw score range is 0-24. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
The Working Memory composite score is calculated by summing the WMS and LNS tscores, ranging from 0-200, a higher tscore reflects better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.76" spread="12.03"/>
                    <measurement group_id="O2" value="33.21" spread="11.86"/>
                    <measurement group_id="O3" value="34.79" spread="10.90"/>
                    <measurement group_id="O4" value="35.70" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.70" spread="10.68"/>
                    <measurement group_id="O2" value="36.41" spread="12.55"/>
                    <measurement group_id="O3" value="36.89" spread="8.94"/>
                    <measurement group_id="O4" value="36.50" spread="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.30" spread="13.08"/>
                    <measurement group_id="O2" value="35.93" spread="12.14"/>
                    <measurement group_id="O3" value="37.54" spread="8.66"/>
                    <measurement group_id="O4" value="35.90" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.13" spread="11.43"/>
                    <measurement group_id="O2" value="36.00" spread="10.99"/>
                    <measurement group_id="O3" value="38.54" spread="9.63"/>
                    <measurement group_id="O4" value="37.20" spread="13.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.86" spread="11.24"/>
                    <measurement group_id="O2" value="38.04" spread="13.08"/>
                    <measurement group_id="O3" value="37.48" spread="9.18"/>
                    <measurement group_id="O4" value="38.00" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Verbal Learning Composite Score Changes</title>
        <description>Verbal learning (composite score of the Hopkins Verbal Learning Test-Revised (HVLT-R)). The HVLT-R has 3 trials in which a subject recalls has many words from a list of 12 as they can. The total number recalled for each trial is summed and the score range is between 0-36. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
The verbal learning composite score is calculated by using the HVLT-R tscore, a higher tscore reflects better performance.</description>
        <time_frame>Baseline, week 2, week 4, week 6, week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY500307 150mg</title>
            <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY500307 75mg</title>
            <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY500307 25mg</title>
            <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Learning Composite Score Changes</title>
          <description>Verbal learning (composite score of the Hopkins Verbal Learning Test-Revised (HVLT-R)). The HVLT-R has 3 trials in which a subject recalls has many words from a list of 12 as they can. The total number recalled for each trial is summed and the score range is between 0-36. The raw score is then converted to a tscore based on normative ranges by age and sex, ranging from 0-100. For both the raw and tscore a higher score reflects better performance.
The verbal learning composite score is calculated by using the HVLT-R tscore, a higher tscore reflects better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.36" spread="6.60"/>
                    <measurement group_id="O2" value="33.93" spread="5.98"/>
                    <measurement group_id="O3" value="34.50" spread="7.39"/>
                    <measurement group_id="O4" value="32.30" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.17" spread="6.97"/>
                    <measurement group_id="O2" value="35.41" spread="8.73"/>
                    <measurement group_id="O3" value="37.11" spread="8.22"/>
                    <measurement group_id="O4" value="34.20" spread="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.96" spread="7.04"/>
                    <measurement group_id="O2" value="35.11" spread="7.43"/>
                    <measurement group_id="O3" value="37.42" spread="8.26"/>
                    <measurement group_id="O4" value="34.60" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.74" spread="6.78"/>
                    <measurement group_id="O2" value="34.44" spread="7.84"/>
                    <measurement group_id="O3" value="34.62" spread="7.13"/>
                    <measurement group_id="O4" value="33.40" spread="6.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.67" spread="5.63"/>
                    <measurement group_id="O2" value="35.54" spread="7.57"/>
                    <measurement group_id="O3" value="37.12" spread="7.76"/>
                    <measurement group_id="O4" value="37.30" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Total Testosterone Reduction</title>
        <description>Number of subjects with total testosterone reduction, as defined as a decrease in total testosterone plasma concentrations of 50% from baseline for two consecutive post-randomization values</description>
        <time_frame>week 2, week 4, week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY500307 150mg</title>
            <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY500307 75mg</title>
            <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY500307 25mg</title>
            <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Total Testosterone Reduction</title>
          <description>Number of subjects with total testosterone reduction, as defined as a decrease in total testosterone plasma concentrations of 50% from baseline for two consecutive post-randomization values</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With QTc Prolongation</title>
        <description>Number of subjects with QTc prolongation, as defined as any subject with a change from baseline of 60 msec or greater during the active treatment phases</description>
        <time_frame>Week 4, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY500307 150mg</title>
            <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY500307 75mg</title>
            <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY500307 25mg</title>
            <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With QTc Prolongation</title>
          <description>Number of subjects with QTc prolongation, as defined as any subject with a change from baseline of 60 msec or greater during the active treatment phases</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cortical Target Engagement</title>
        <description>To determine if LY500307 demonstrates cortical target engagement as assessed by changes in the N-back in frontal-parietal regions during the MRI.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LY500307 150mg</title>
            <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>LY500307 75mg</title>
            <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>LY500307 25mg</title>
            <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cortical Target Engagement</title>
          <description>To determine if LY500307 demonstrates cortical target engagement as assessed by changes in the N-back in frontal-parietal regions during the MRI.</description>
          <units>beta coefficient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.22"/>
                    <measurement group_id="O2" value="0.16" spread="0.22"/>
                    <measurement group_id="O3" value="0.27" spread="0.21"/>
                    <measurement group_id="O4" value="0.21" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.21"/>
                    <measurement group_id="O2" value="0.22" spread="0.22"/>
                    <measurement group_id="O3" value="0.31" spread="0.26"/>
                    <measurement group_id="O4" value="0.30" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the 8 week time period that subjects were enrolled in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo 6 pills of inactive drug
Placebo: 6 placebo capsules daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>LY500307 25mg</title>
          <description>LY500307 25mg
LY500307 25mg: LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>LY500307 75mg</title>
          <description>LY500307 75mg
LY500307 75mg: LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks</description>
        </group>
        <group group_id="E4">
          <title>LY500307 150mg</title>
          <description>LY500307 150mg
LY500307 150mg: LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Psychotic Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Urinary Frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alan Breier</name_or_title>
      <organization>Indiana University</organization>
      <phone>3178808495</phone>
      <email>abreier@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

